MedTrace Logo

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

NCT06275373 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-02-23

No results posted yet for this study

Summary

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Conditions

  • Thyroid Eye Disease
  • Graves Ophthalmopathy
  • Graves Disease

Interventions

DRUG

Teprotumumab Injection [Tepezza]

IGF1 monoclonal antibody

Sponsors & Collaborators

  • Walter Reed National Military Medical Center

    lead FED

Principal Investigators

  • Thanh D Hoang, DO · Walter Reed National Military Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2026-05-12
Completion
2027-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06275373 on ClinicalTrials.gov